Wed, 24/06/09 – 7:42 | No Comment

Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …

Read the full story »
Aim to Cure

A focus on disease-specific efforts by pharmaceutical and biotech companies

Analysis

Read in depth analysis by industry experts on investing opportunities and business strategies

Company Profiles

Learn about corporate strategies, positioning and investing opportunities

Industry News

Stay on top of the industry with our industry news bulletin

Mutual Funds

Diversify to hedge your investment during economic turbulence

Home » Aim to Cure, Analysis, Featured, Headline, Industry News

HCPC Calls For Greater Healthcare Savings Through Improved Adherence To Prescription Drug Regimens

Submitted by Robert Lawrence on Wednesday, 24 June 2009No Comment

With today’s announcement that the Pharmaceutical Research and Manufacturers of America (PhRMA) has offered to voluntarily grant some $80 billion in discounts to Medicare beneficiaries over the next decade in an effort to reduce overall healthcare costs, the Healthcare Compliance Packaging Council (HCPC) noted that far greater savings can be achieved if immediate steps are taken to help people take their prescription drugs properly.

Leave a comment!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.